

# Resource Summary Report

Generated by [kravitz2](#) on Aug 11, 2026

## CD8a Monoclonal Antibody (4SM15), Biotin, eBioscience

RRID:AB\_2572771

Type: Antibody

### Proper Citation

(Thermo Fisher Scientific Cat# 13-0808-82, RRID:AB\_2572771)

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2572771](http://antibodyregistry.org/AB_2572771)

**Proper Citation:** (Thermo Fisher Scientific Cat# 13-0808-82, RRID:AB\_2572771)

**Target Antigen:** CD8a

**Host Organism:** rat

**Clonality:** monoclonal

**Comments:** Applications: Flow, IHC-P

**Antibody Name:** CD8a Monoclonal Antibody (4SM15), Biotin, eBioscience

**Description:** This monoclonal targets CD8a

**Target Organism:** mouse

**Clone ID:** Clone 4SM15

**Antibody ID:** AB\_2572771

**Vendor:** Thermo Fisher Scientific

**Catalog Number:** 13-0808-82

**Alternative Catalog Numbers:** 13-0808

**Record Creation Time:** 20251213T073209+0000

**Record Last Update:** 20260225T230345+0000

### Ratings and Alerts

No rating or validation information has been found for CD8a Monoclonal Antibody (4SM15), Biotin, eBioscience.

No alerts have been found for CD8a Monoclonal Antibody (4SM15), Biotin, eBioscience.

---

## Data and Source Information

**Source:** [Antibody Registry](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [kravitz2](#) .

Pfefferkorn AM, et al. (2026) Injured epithelial cell states impact kidney allograft survival after T-cell-mediated rejection. Nature communications, 17(1), 1060.

Lubrano S, et al. (2025) FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma. Cancer cell, 43(3), 428.

Oami T, et al. (2024) Claudin-2 upregulation enhances intestinal permeability, immune activation, dysbiosis, and mortality in sepsis. Proceedings of the National Academy of Sciences of the United States of America, 121(10), e2217877121.

Perkins DW, et al. (2024) Therapy-induced normal tissue damage promotes breast cancer metastasis. iScience, 27(1), 108503.

Heiser RA, et al. (2024) Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity. Molecular cancer therapeutics, 23(1), 68.